Literature DB >> 19714640

Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis.

Georg Schett1, Marina Stolina, Denise Dwyer, Debra Zack, Stefan Uderhardt, Gerhard Krönke, Paul Kostenuik, Ulrich Feige.   

Abstract

OBJECTIVE: To investigate the kinetics of bony spur formation and the relationship of bony spur formation to synovial inflammation and bone erosion in 2 rat arthritis models, and to address whether bony spur formation depends on the expression of tumor necrosis factor alpha (TNFalpha) or RANKL.
METHODS: Analysis of the kinetics of synovial inflammation, bone erosion, osteoclast formation, and growth of bony spurs was performed in rat collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA). In addition, inhibition experiments were performed to assess whether inhibition of TNFalpha and RANKL by pegylated soluble TNF receptor type I (pegTNFRI) and osteoprotegerin (OPG), respectively, affected bony spur formation.
RESULTS: Bony spurs emerged from the periosteal surface close to joints, and initial proliferation of mesenchymal cells was noted as early as 3 days and 5 days after onset of CIA and AIA, respectively. Initiation of bony spur formation occurred shortly after the onset of inflammation and bone erosion. Neither pegTNFRI nor OPG could significantly halt the osteophytic responses in CIA and AIA.
CONCLUSION: These results suggest that bony spur formation is triggered by inflammation and initial structural damage in these rat models of inflammatory arthritis. Moreover, emergence of bony spurs depends on periosteal proliferation and is not affected by inhibition of either TNFalpha or RANKL. Bony spur formation can thus be considered a process that occurs independent of TNFalpha and RANKL and is triggered by destructive arthritis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19714640     DOI: 10.1002/art.24767

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  23 in total

1.  Pathophysiology of spondyloarthritis.

Authors:  Monika Ronneberger; Georg Schett
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

Review 2.  The balance of tissue repair and remodeling in chronic arthritis.

Authors:  Rik Lories
Journal:  Nat Rev Rheumatol       Date:  2011-10-18       Impact factor: 20.543

3.  Alternative for anti-TNF antibodies for arthritis treatment.

Authors:  Joseph Paquet; Christel Henrionnet; Astrid Pinzano; Jean-Baptiste Vincourt; Pierre Gillet; Patrick Netter; Isabelle Chary-Valckenaere; Damien Loeuille; Jacques Pourel; Laurent Grossin
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

4.  Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human β2 -microglobulin-transgenic rat model of spondylarthritis.

Authors:  Leonie M van Duivenvoorde; Martha L Dorris; Nimman Satumtira; Melissa N van Tok; Kurt Redlich; Paul P Tak; Joel D Taurog; Dominique L Baeten
Journal:  Arthritis Rheum       Date:  2012-10

5.  Advances in rheumatoid arthritis animal models.

Authors:  Kamal D Moudgil; Peter Kim; Ernest Brahn
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

Review 6.  Osteoporosis in inflammatory joint diseases.

Authors:  C Roux
Journal:  Osteoporos Int       Date:  2010-06-15       Impact factor: 4.507

Review 7.  Impact of inflammation on the osteoblast in rheumatic diseases.

Authors:  Rebecca Baum; Ellen M Gravallese
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

8.  Dickkopf-1 directs periosteal bone formation in two murine models of inflammatory arthritis.

Authors:  A T Shaw; J Yan; S A Kuhstoss; J F Charles; E M Gravallese
Journal:  Scand J Rheumatol       Date:  2022-03-11       Impact factor: 3.057

Review 9.  Osteochondral tissue engineering: scaffolds, stem cells and applications.

Authors:  Patcharakamon Nooeaid; Vehid Salih; Justus P Beier; Aldo R Boccaccini
Journal:  J Cell Mol Med       Date:  2012-10       Impact factor: 5.310

10.  High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteoblast differentiation.

Authors:  Eun-Ju Lee; Eun-Jin Lee; Yeon-Ho Chung; Da-Hyun Song; Seokchan Hong; Chang-Keun Lee; Bin Yoo; Tae-Hwan Kim; Ye-Soo Park; Soo-Hyun Kim; Eun-Ju Chang; Yong-Gil Kim
Journal:  Arthritis Res Ther       Date:  2015-12-04       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.